http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
-
Bicycle Therapeutics (BCYC) and Bayer Collaborate for Development of Novel Targeted Radionuclide Therapies in Oncology
-
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
-
Bayer and Bicycle Therapeutics (BCYC) Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
-
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
-
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
-
BioMed Realty Leases 96,000 Square Feet at the Company’s Flagship Granta Park Campus in Cambridge
-
Annual Changes to the Nasdaq Biotechnology Index
-
OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins
-
Ionis reports third quarter 2021 financial results and recent business achievements
-
Ionis reports second quarter 2021 financial results and recent business achievements
-
Ionis Pharmaceuticals (IONS) enters pact with Bicycle Therapeutics (BCYC) aimed at further advancing LICA technology
-
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
-
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
-
Annual results for the year ended 31 March 2020
-
Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage
-
Cambridge Innovation Capital has attracted £1 billion of investment into Cambridge companies
-
Bicycle Therapeutics to Present New Translational Data for BT1718 and Preclinical Data for Other Bicycle® Toxin Conjugates at AACR-NCI-EORTC 2019
-
Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
-
Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
-
Bicycle Therapeutics Plc (BCYC) Announces Richard N. Kender and Janice Bourque to Board
-
Bicycle Therapeutics Enhances Board of Directors
-
Bicycle Therapeutics Plc (BCYC) Announces Positive Topline Results from Oxurion's Phase I Trial Using Novel Bicycle-based Plasma Kallikrein Inhibitor for Treatment of DME
-
Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
-
Annual results for the year ended 31 March 2019
-
Citi Appointed as Depositary Bank for Bicycle Therapeutics’ ADR Programme

